EMCDDA Home
  • EN
Search

Figure GPS-17. Last 12 months prevalence of amphetamines, ecstasy and cocaine use among young adults (aged 15–34)

 
 
CountryAmphetaminesEcstasyCocaine
Related links:
TR (2011):0.1:
RO (2010)0.00.40.2
EL (2004)0.10.40.2
LT (2008)1.11.90.3
LV (2011)0.60.80.3
HU (2007)1.21.00.4
SK (2010)0.30.90.4
NO (2009)0.80.80.6
FI (2010)1.61.10.6
HR (2012)1.60.50.9
CZ (2011)1.42.51.1
PT (2007)0.40.91.2
AT (2008)0.91.01.2
SE (2008)1.50.21.2
PL (2010)3.93.11.3
EE (2008)2.52.31.3
IT (2012)0.10.11.3
BG (2008)2.11.61.5
DE (2009)1.91.01.8
FR (2010)0.50.41.9
CY (2009)0.71.02.2
NL (2009):3.12.4
DK (2010)2.00.82.5
IE (2010/11)0.80.92.8
ES (2011)1.11.43.6
UK (E&W) (2011/12)1.42.84.2
Statistical bulletin 2006: Figure GPS-23 part (i)
Statistical bulletin 2007: Figure GPS-17
Statistical bulletin 2008: Figure GPS-17
Statistical bulletin 2009: Figure GPS-17
Statistical bulletin 2010: Figure GPS-17
Statistical bulletin 2011: Figure GPS-17
Statistical bulletin 2012: Figure GPS-18
See also Tables GPS-2 part ii and GPS-2 part iii
See also 'General notes for interpreting data' on the Explanatory notes and help page

Notes:

Sample sizes (n) refer to the number of respondents for 15- to 34-year-old group. For number of respondents for the whole surveys, see Epidemiological tables on population surveys in the Statistical bulletin 2013.

Data are from the most recent national surveys available in each country (see General population survey tables, Statistical bulletin 2013).

For young adults, the EMCDDA standard age range is 15 to 34 years (Denmark and the UK from 16 years, Estonia, Hungary and Germany from 18 years). Variations in age ranges may slightly influence some national differences. In some countries, the figures were recalculated at national level, to adapt as far as possible to standard EMCDDA age groups.

The most recent general population survey reported by the Netherlands display a wide variation in results compared with 2005 which may reflect methodological differences. The data is provided for information, but given the lack of comparability between surveys should be treated with caution.

The most recent general population survey reported by Italy display a wide variation in results compared with the previous surveys which may reflect methodological differences. The data is provided for information, but given the lack of comparability between surveys should be treated with caution.

Bulgaria: 2008; n=2164

Czech Republic: 2011; n=361

Denmark: 2010; n=3381

Germany: 2009; n=3876

Estonia: 2008; n=545

Ireland: 2010/11; n=n.a.

Greece: 2004; n=2620

Spain: 2011; n=10507

France: 2010; n=10855

Italy: 2012; n=4966

Cyprus: 2009; n=1810

Latvia: 2011; n =2258

Lithuania: 2008; n=2152

Hungary: 2007; n=1111

Netherlands: 2009; n=n.a.

Austria: 2008; n=2558

Poland: 2010; n=3201

Portugal: 2007; n=4765

Romania: 2010; n=3108

Slovakia: 2010; n=1769

Finland: 2010; n=875

Sweden: 2008; n=16271

UK (E&W): 2011/12; n=9691

Croatia: 2012; n=1995

Turkey: 2011; n=4039

Norway: 2009; n=632

Sources:

Reitox national reports 2012, taken from surveys, reports or scientific articles.

  Amphetamines Ecstasy Cocaine
TR (2011) 0 0.1 0
RO (2010) 0.0 0.4 0.2
EL (2004) 0.1 0.4 0.2
LT (2008) 1.1 1.9 0.3
LV (2011) 0.6 0.8 0.3
HU (2007) 1.2 1.0 0.4
SK (2010) 0.3 0.9 0.4
NO (2009) 0.8 0.8 0.6
FI (2010) 1.6 1.1 0.6
HR (2012) 1.6 0.5 0.9
CZ (2011) 1.4 2.5 1.1
PT (2007) 0.4 0.9 1.2
AT (2008) 0.9 1.0 1.2
SE (2008) 1.5 0.2 1.2
PL (2010) 3.9 3.1 1.3
EE (2008) 2.5 2.3 1.3
IT (2012) 0.1 0.1 1.3
BG (2008) 2.1 1.6 1.5
DE (2009) 1.9 1.0 1.8
FR (2010) 0.5 0.4 1.9
CY (2009) 0.7 1.0 2.2
NL (2009) 0 3.1 2.4
DK (2010) 2.0 0.8 2.5
IE (2010/11) 0.8 0.9 2.8
ES (2011) 1.1 1.4 3.6
UK (E&W) (2011/12) 1.4 2.8 4.2

gpsfig17

 

About the EMCDDA

The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is the reference point on drugs and drug addiction information in Europe. Inaugurated in Lisbon in 1995, it is one of the EU's decentralised agencies. Read more >>

Contact us

EMCDDA
Praça Europa 1, Cais do Sodré
1249-289 Lisbon
Portugal
Tel. (351) 211 21 02 00
Fax (351) 218 13 17 11

More contact options >>

Page last updated: Wednesday, 08 May 2013